Skip to main content
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. — Investor Relations & Filings

Ticker · ANTX ISIN · US0373261058 US Manufacturing
Open in API
Filings indexed 339 across all filing types
Latest filing 2022-11-10 Director's Dealing
Country US United States of America
Listing US ANTX

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com/

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing treatments for rare, chronic, and serious infectious diseases with high unmet medical needs. The company utilizes its proprietary boron chemistry platform to create novel small molecule therapeutics. Its development pipeline includes boron-based compounds, such as its lead candidate epetraborole, which are being investigated as potential first-in-class or best-in-class therapies. The company's mission is to deliver high-impact drugs to improve global health outcomes, with potential applications extending to oncology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-11-10 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2022, reporting the issuance of a press release announcing financial results for the third quarter ended September 30, 2022. The text states that the full press release is attached as an exhibit and incorporated by reference, but the document itself does not contain the financial results or detailed financial statements. The document is short (3536 characters) and primarily serves as a notification of the earnings release rather than the earnings release itself. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results, but since the full financial details are in the attached press release, this 8-K serves as the initial announcement of those results.
2022-11-09 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-03 English
FORM 4 SUBMISSION
Director's Dealing
2022-10-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.